首发精神分裂症患者中ZNF804A rs1344706多态性与非典型抗精神病药疗效间的关联分析

Association analysis between ZNF804A rs1344706 polymorphism and therapeutic response to atypical antipsychotics in first-episode Chinese schizophrenia patients

目的:研究首发精神分裂症患者中ZNF804A基因rs1344706多态性与非典型抗精神病药疗效间潜在的关系。方法:71例首发精神分裂症住院患者作为研究对象,随机接受奥氮平、齐拉西酮或阿立哌唑单药治疗4周,所有受试者在基线和治疗结束时均接受1次阳性和阴性症状量表(PANSS)的评定,利用直接测序法确定每位受试者的ZNF804A rs1344706位点的基因型。结果:3组不同基因型的首发精神分裂症患者其治疗前后PAN-SS总分及阳性因子分的变化存在着显著差异(PANSS总分:F=4.608,df=2,P<0.05;PANSS阳性因子分:F=4.183,df=2,P<0.05);T携带者的PANSS总分和阳性因子分的改善显著小于G纯合子患者(PANSS总分:F=8.724,df=1,P<0.01;PANSS阳性因子分:F=9.392,df=1,P<0.01)。结论:在首发精神分裂症患者中,ZNF804A rs1344706基因型与非典型抗精神病药物的疗效呈显著相关。

AIM： To investigate the potential association between ZNF804A rs1344706 polymorphism and therapeutic response to atypical antipsychotics in first-episode Chinese schizophrenia patients.METHODS： Seventy-one first-episode schizophrenia inpatients receiving olanzapine,aripiprazole or quetiapine monotherapy were enrolled.Symptom responses to the treatment were assessed using the positive and negative symptom scale（PANSS） at the time of admission and re-assessed after 4 weeks of treatment.The single nucleotide polymorphism（SNP） rs1344706 was genotyped by direct sequencing.RESULTS： There was substantial difference of treatment response among the patients with 3 different genotypes regarding total PANSS score and positive subscore（for total PANSS score,F=4.608,df=2,P0.05;for positive subscore,F=4.183,df=2,P0.05）.Compared with G homozygotes,T carriers showed significantly less improvement in total PANSS score as well as positive subscore（for total PANSS score,F=8.724,df=1,P0.01,for positive subscore,F=9.392,df=1,P0.01）.CONCLUSION： Our results suggest that significant correlation exists between ZNF804A rs1344706 polymorphism and therapeutic response to atypical antipsychotics among the first-episode of schizophrenia,although replication is required to confirm this finding.